- Home
- NGNE vs DRDB Comparison
NGNE vs DRDB Comparison
Compare NGNE & DRDB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NGNE
- DRDB
- Stock Information
- Founded
- NGNE 2003
- DRDB 2024
- Country
- NGNE United States
- DRDB United States
- Employees
- NGNE N/A
- DRDB N/A
- Industry
- NGNE Biotechnology: Pharmaceutical Preparations
- DRDB
- Sector
- NGNE Health Care
- DRDB
- Exchange
- NGNE Nasdaq
- DRDB Nasdaq
- Market Cap
- NGNE 325.3M
- DRDB 315.3M
- IPO Year
- NGNE N/A
- DRDB 2024
- Fundamental
- Price
- NGNE $20.51
- DRDB $10.28
- Analyst Decision
- NGNE Strong Buy
- DRDB
- Analyst Count
- NGNE 7
- DRDB 0
- Target Price
- NGNE $41.86
- DRDB N/A
- AVG Volume (30 Days)
- NGNE 123.0K
- DRDB 127.4K
- Earning Date
- NGNE 08-11-2025
- DRDB 01-01-0001
- Dividend Yield
- NGNE N/A
- DRDB N/A
- EPS Growth
- NGNE N/A
- DRDB N/A
- EPS
- NGNE N/A
- DRDB N/A
- Revenue
- NGNE N/A
- DRDB N/A
- Revenue This Year
- NGNE N/A
- DRDB N/A
- Revenue Next Year
- NGNE N/A
- DRDB N/A
- P/E Ratio
- NGNE N/A
- DRDB $587.25
- Revenue Growth
- NGNE N/A
- DRDB N/A
- 52 Week Low
- NGNE $6.88
- DRDB $9.87
- 52 Week High
- NGNE $74.49
- DRDB $10.43
- Technical
- Relative Strength Index (RSI)
- NGNE 47.72
- DRDB N/A
- Support Level
- NGNE $18.94
- DRDB N/A
- Resistance Level
- NGNE $21.59
- DRDB N/A
- Average True Range (ATR)
- NGNE 1.40
- DRDB 0.00
- MACD
- NGNE -0.26
- DRDB 0.00
- Stochastic Oscillator
- NGNE 32.30
- DRDB 0.00
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
About DRDB Roman DBDR Acquisition Corp. II Ordinary shares
Roman DBDR Acquisition Corp II is a blank check company.